Diabetic Retinopathy Clinical Trials 2024: FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight

(Albany, USA) DelveInsight's, "Diabetic Retinopathy Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Diabetic Retinopathy pipeline landscape. It covers the Diabetic Retinopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetic Retinopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Diabetic Retinopathy Pipeline Report
• DelveInsight's Diabetic Retinopathy pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline therapies for Diabetic Retinopathy treatment.
• The leading companies working in the Diabetic Retinopathy Market include Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
• Promising Diabetic Retinopathy Pipeline Therapies in the various stages of development include Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.
• April 2024: Bayer announced a study of Phase 2 clinical trials for Runcaciguat (BAY1101042). This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography for central assessment of the diabetic retinopathy severity score, or DRSS.
• March 2024: Aviceda Therapeutics Inc. announced a study of Phase 2 clinical trials for AVD-104. The primary objective is to evaluate the tolerability and treatment effect of intravitreal injections (IVT) of AVD-104 in participants with diabetic macular edema (DME). Participants will receive either three intravitreal injections of low-dose AVD-104 (1.0 mg) each 28 days apart or two intravitreal injections of AVD-104 at a high-dose (2.0 mg) 56 days apart.

Request a sample and discover the recent advances in Diabetic Retinopathy Treatment Drugs @ Diabetic Retinopathy Pipeline Outlook Report- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

In the Diabetic Retinopathy pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Diabetic Retinopathy Overview
Diabetic retinopathy (DR) is a major complication of diabetes mellitus (DM), which remains a leading cause of visual loss in working-age populations. The retina contains photoreceptor cells that function in the process of visual transduction, i.e., transforming light signals to nerve impulses eventually transmitted from the optic nerve to the brain forming an image.

Find out more about Diabetic Retinopathy Therapeutics Assessment @ Diabetic Retinopathy Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diabetic Retinopathy Emerging Drugs Profile

• Brolucizumab: Novartis
Brolucizumab (RTH258) is a humanized single-chain antibody fragment (scFv) and the most clinically advanced, humanized single-chain antibody fragment to reach this stage of development. Single-chain antibody fragments are highly sought after in drug development due to their small size, enhanced tissue penetration, rapid clearance from systemic circulation, and drug delivery characteristics. The proprietary, innovative structure results in a small molecule (26 kDa) with potent inhibition of and high affinity to, all VEGF-A isoforms. In preclinical studies, brolucizumab inhibited activation of VEGF receptors through prevention of the ligand-receptor interaction. Increased signaling through the VEGF pathway is associated with pathologic ocular angiogenesis and retinal edema. Inhibition of the VEGF pathway has been shown to inhibit the growth of neovascular lesions, resolve retinal edema and improve vision in patients with chorioretinal vascular diseases. Currently, the drug is in Phase III stage of development to treat Diabetic Retinopathy.

• RGX 314: Regenxbio Inc.
RGX-314 is being developed as a novel, one-time subretinal treatment that includes the NAV AAV8 vector containing a gene encoding for a monoclonal antibody fragment. The expressed protein is designed to neutralize vascular endothelial growth factor (VEGF) activity, modifying the pathway for the formation of new leaky blood vessels and retinal fluid accumulation. The company is currently enrolling patients in ALTITUDE, a Phase II trial for the treatment of diabetic retinopathy using suprachoroidal delivery of RGX-314.

• OTT-166: OcuTerra Therapeutics
OTT-166 is a novel small molecule selective integrin inhibitor that OcuTerra has purpose-engineered to have the required physiochemical characteristics to be able to reach the retina from eye drop application. Phase 1b clinical trials of OTT-166 eye drops have demonstrated safety, tolerability, and clear clinical evidence of biological activity. OcuTerra is currently studying the safety, efficacy, and optimal dosing regimen of OTT166 through the Phase II DR: EAM (Diabetic Retinopathy: Early Active Management) study in patients with moderately-severe to severe non-proliferative and mild proliferative diabetic retinopathy.

• OTX-TKI: Ocular Therapeutix
OTX-TKI is an investigational bioresorbable hydrogel implant incorporating axitinib, a small molecule tyrosine kinase inhibitor with anti-angiogenic properties. The drug is currently being evaluated in Phase I for the treatment of diabetic retinopathy.

Diabetic Retinopathy Therapeutics Assessment
There are approx. 50+ key Diabetic Retinopathy companies which are developing the Diabetic Retinopathy therapies. The Diabetic Retinopathy companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. phase III include, Kodiak Sciences.

DelveInsight's Diabetic Retinopathy pipeline report covers around 55+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Diabetic Retinopathy Pipeline Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Learn more about the emerging Diabetic Retinopathy Pipeline Therapies @ Diabetic Retinopathy Clinical Trials Assessment- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Scope of the Diabetic Retinopathy Pipeline Report
• Coverage- Global
• Diabetic Retinopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Diabetic Retinopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Diabetic Retinopathy Companies- Kodiak Sciences, Novartis, Regenxbio Inc., OcuTerra Therapeutics, Ocular Therapeutix, Bayer, RemeGen, Roche, Ocuphire Pharma, Adverum Biotechnologies, Boehringer Ingelheim, and others.
• Diabetic Retinopathy Pipeline Therapies- Runcaciguat (BAY1101042), OTT166, COLIRIOBCN070660, Brimonidine, and others.

Dive deep into rich insights for new drugs for Diabetic Retinopathy Treatment, Visit @ Diabetic Retinopathy Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Content
1. Introduction
2. Executive Summary
3. Diabetic Retinopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Diabetic Retinopathy- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. KSI-301: Kodiak Sciences
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RGX 314: Regenxbio Inc
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OTX-TKI: Ocular Therapeutix
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Diabetic Retinopathy Key Companies
21. Diabetic Retinopathy Key Products
22. Diabetic Retinopathy- Unmet Needs
23. Diabetic Retinopathy- Market Drivers and Barriers
24. Diabetic Retinopathy- Future Perspectives and Conclusion
25. Diabetic Retinopathy Analyst Views
26. Diabetic Retinopathy Key Companies
27. Appendix

For further information on the Diabetic Retinopathy Pipeline therapeutics, reach out to Diabetic Retinopathy Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/diabetic-retinopathy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• Acute On Liver Failure Market: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
• Adrenoleukodystrophy Market: https://www.delveinsight.com/report-store/adrenoleukodystrophy-market
• Atypical Hemolytic Uremic Syndrome Ahus Market: https://www.delveinsight.com/report-store/atypical-hemolytic-uremic-syndrome-ahus-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Eosinophilic Asthma Market: https://www.delveinsight.com/report-store/eosinophilic-asthma-market
• Gene And Cell Therapies In Rare Disorder Market: https://www.delveinsight.com/report-store/gene-and-cell-therapies-in-rare-disorder-market
• Generalized Pustular Psoriasis Market: https://www.delveinsight.com/report-store/generalized-pustular-psoriasis-market
• Malt Lymphoma Market: https://www.delveinsight.com/report-store/marginal-zone-lymphoma-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Nonmuscle Invasive Bladder Cancer Market: https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market
• Oral Mucositis Om Market: https://www.delveinsight.com/report-store/oral-mucositis-om-market
• Parkinson S Disease Levodopa Induced Dyskinesia Market: https://www.delveinsight.com/report-store/parkinsons-disease-levodopa-induced-dyskinesia-market#:~:text=In%202023%2C%20the%20total%20market,approximately%20USD%20900%20thousand%20million.
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
• Polycythemia Market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Pulmonary Hypertension Associated With Interstitial Lung Disease Market: https://www.delveinsight.com/report-store/pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild-market
• Refractory Chronic Cough Market: https://www.delveinsight.com/report-store/chronic-refractory-cough-market
• Uncomplicated Urinary Tract Infections Market: https://www.delveinsight.com/report-store/uncomplicated-urinary-tract-infection-uuti-market
• Adrenal Crisis Market: https://www.delveinsight.com/report-store/adrenal-crisis-market
• Alstrom Syndrome Market: https://www.delveinsight.com/report-store/alstrom-syndrome-market
• Car T Therapy For Acute Lymphoblastic Leukemia All Market: https://www.delveinsight.com/report-store/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-market
• Cervical Cancer Market Size: https://www.delveinsight.com/report-store/cervical-cancer-market
• Leber's Hereditary Optic Neuropathy Market: https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case Study: https://www.delveinsight.com/case-study/cdmo-competitive-assessment

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.